# Eyebiotech

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/eyebiotech

- Industry: Biotechnology
- Headquarters: London, UK
- Website: www.eyebiotech.com
- Total disclosed funding: $31M
- Latest round: Series A (Feb 3, 2022)
- Investors on record: 4

## About

Based in London, UK, and founded in 2021 by David Guyer and Anthony P. Adamis, Eyebiotech Limited operates as an ophthalmology biotechnology company. In February 2022, Eyebiotech Limited raised USD 65 million in Series A funding co-led by SV Health Investors including Samsara BioCapital, Jeito Capital, and MRL Ventures Fund. As of 2022, David Guyer is the president and CEO of the company. In May 2024, Merck & Co., Inc. agreed to fully acquire Eyebiotech Limited from Bain Capital Life Sciences, Jeito Capital, MRL Ventures Fund, Omega Funds, Samsara BioCapital, SV Health Investors, and Vertex Ventures HC for USD 1.3 billion.

The company develops and delivers a new generation of therapies to protect, restore, and improve vision in patients with sight-threatening eye diseases. The firm provides anti-vascular endothelial growth factor (anti-VEGF) therapy for patients with age-related macular degeneration (AMD).

The organization plans to use the February 2022 funding to develop more products in its pipeline.

## Funding rounds

- Series A, Feb 3, 2022, $31M — SV Health Investors, Samsara BioCapital, MRL Ventures Fund, Jeito Capital

## Investors

- SV Health Investors (https://capitalatlas.ai/funds/sv-health-investors) — Series A
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series A
- MRL Ventures Fund (https://capitalatlas.ai/funds/mrl-ventures-fund) — Series A
- Jeito Capital (https://capitalatlas.ai/funds/jeito-capital) — Series A